Your session is about to expire
← Back to Search
Amlitelimab for Atopic Dermatitis/Eczema (HYDRO Trial)
HYDRO Trial Summary
This trial is to assess the safety and effectiveness of amlitelimab on vaccine responses in adults with moderate-to-severe atopic dermatitis.
HYDRO Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowHYDRO Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.HYDRO Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the U.S. Food and Drug Administration given its stamp of approval to Amlitelimab?
"Our team rated the safety of Amlitelimab as a 2 out of 3. This is due to its Phase 2 classification, which confirms some evidence for safety but not efficacy."
To what extent is the cohort in this research study being treated?
"Affirmative. Clinicaltrials.gov provides evidence that this research study, which was opened on 10/6/2023, is actively seeking participants. 166 volunteers are required from 5 different clinical sites."
How many healthcare settings in Canada are engaged with this clinical experiment?
"Five distinct locations are hosting this clinical trial: Hamilton, London, Newmarket and two further unspecified sites. The corresponding investigational site numbers for each location are 1240020, 1240017, and 1240018 respectively."
Is the opportunity for enrolment in this research still available?
"Affirmative. Per the information on clinicaltrials.gov, this scientific investigation is currently recruiting patients and was initially posted October 6th 2023; with its last update being October 27th 23rd. The trial has a target enrolment of 166 participants at 5 different facilities."
Share this study with friends
Copy Link
Messenger